Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lumacaftor/Ivacaftor in young children with Cystic Fibrosis
NCT03625466Phase 2Completed
- Sponsor
- Vertex Pharmaceuticals
- Start
- Aug 2018
- Primary completion
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of lumacaftor and ivacaftor in cystic fibrosis (CF), sponsored by Vertex Pharmaceuticals. Started Aug 2018; status: completed.
02
Drugs
lumacaftorivacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT03625466.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03625466.